Skip to main content
logo
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
14.86
-0.14 (-0.93%)
At close: Nov 6, 2026, 4:00 PM EST
14.82
-0.04 (-0.27%)
After-hours: Nov 6, 2026, 7:46 PM EST

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
3656541874898651,861
Market Cap Growth
14.98%249.70%-61.73%-43.52%-53.52%-
Enterprise Value
216387-215-45182992
Last Close Price
14.8630.7812.8038.8069.40154.80

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
24356.1018163.583065.303758.6610.22174.77
PB Ratio
1.902.640.490.751.042.00
P/TBV Ratio
1.902.640.490.751.042.00

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
14375.9010759.39--2.1593.15

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.230.210.150.100.080.07
Net Debt / Equity Ratio
-0.78-0.79-0.85-0.76-0.77-0.89
Net Debt / EBITDA Ratio
0.781.051.632.223.804.15
Net Debt / FCF Ratio
1.071.301.993.003.324.33
Asset Turnover
00000.080.01
Quick Ratio
3.835.006.8915.8217.2913.15
Current Ratio
4.025.287.0616.0717.5913.40
Return on Equity (ROE)
-97.79%-86.98%-66.10%-31.53%-20.77%-30.36%
Return on Assets (ROA)
-36.90%-29.83%-22.05%-18.18%-11.32%-13.11%
Return on Capital Employed (ROCE)
-88.40%-68.20%-50.10%-34.30%-20.80%-19.80%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-76.13%-41.97%-183.44%-48.02%-21.17%-13.44%
FCF Yield
-38.31%-23.06%-87.10%-34.05%-22.40%-10.30%
Buyback Yield / Dilution
-45.86%-30.74%-4.18%-1.58%-81.79%-925.18%
SEC Filings: 10-K · 10-Q